Alto Neuroscience, a Los Altos, CA-based neuro-tech company which specializes in precision psychiatry, raises $35M Series B Financing … The company intends to use the funds to advance lead candidates into Phase 2b studies in major depressive disorder … Proceeds from the financing will also be used to progress the company’s artificial intelligence-enabled brain biomarker platform and launch new clinical trials in areas of high unmet medical need. Alto will report Phase 2a data in early 2023 and further anticipates Phase 2b data readouts by early 2024. [Read more…] about Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform
Brain-wave pattern can identify people likely to respond to antidepressant, study finds (Stanford Medicine press release):
“A new method of interpreting brain activity could potentially be used in clinics to help determine the best treatment options for depression, according to a study led by researchers at the Stanford School of Medicine.
Stanford researchers and their collaborators used electroencephalography, a tool for monitoring electrical activity in the brain, and an algorithm to identify a brain-wave signature in [Read more…] about Machine-learning study finds EEG brain signatures that predict response to antidepressant treatments